MiRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer

Cell Death and Disease

Volumn 7, Issue 6, 2016, Pages

  Hu, Y ^a,b   Qiu, Y ^a   Yague E ^c   Ji, W ^b   Liu, J ^a   Zhang, J ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; MICRORNA 205; PACLITAXEL; PROTEIN BAX; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CELL GROWTH FACTOR A; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CASPASE; MESSENGER RNA; MICRORNA; MIRN205 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN A;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; DRUG SENSITIVITY; DRUG-RESISTANT CELL LINE; ECTOPIC EXPRESSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STABLE EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ADJUVANT CHEMOTHERAPY; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; CELL PROTECTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CYTOPROTECTION; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TREATMENT OUTCOME; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85019674669     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.194     Document Type: Article

References (61)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
2. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958–4965.
3. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5: 372–380.
4. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4: 232–245.
5. Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 2014; 25: 1128–1136.
6. Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 2015; 26: 325–332.
7. Borst P, Wessels L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 2010; 9: 4836–4840.
8. Wang J, Yang M, Li Y, Han B. The role of microRNAs in the chemoresistance of breast cancer. Drug Dev Res 2015; 76: 368–374.
9. Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res 2015; 17: 40.
10. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 2015; 6: 37269–37280.
11. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
12. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009; 11: R27.
13. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497: 378–382.
14. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152–2159.
15. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127–19137.
16. Hu Y, Li K, Asaduzzaman M, Cuella R, Shi H, Raguz S et al. miR-106b ~ 25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 2016; 35: 1170–1178.
17. Zhou Y, Hu Y, Yang M, Jat P, Li K, Lombardo Y et al. The miR-106b ~ 25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death Differ 2014; 21: 462–474.
18. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res 2013; 25: 46–54.
19. von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31: 3623–3630.
20. Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y et al. Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol 2013; 85: 186–196.
21. Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng T et al. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 2013; 72: 789–798.
22. Su Y, Cheng X, Tan Y, Hu Y, Zhou Y, Liu J et al. Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms. PLoS One 2012; 7: e32782.
23. Hu Y, Xu K, Yague E. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat 2015; 151: 269–280.
24. Wang L, Shan M, Liu Y, Yang F, Qi H, Zhou L et al. miR-205 suppresses the proliferative and migratory capacity of human osteosarcoma Mg-63 cells by targeting VEGFA. Onco Targets Ther 2015; 8: 2635–2642.
25. Salajegheh A, Vosgha H, Md Rahman A, Amin M, Smith RA, Lam AK. Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. J Mol Endocrinol 2015; 55: 183–196.
26. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130–23140.
27. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326(Pt 1): 1–16.
28. Wen X, Lin ZQ, Liu B, Wei YQ. Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif 2012; 45: 217–224.
29. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273: 9357–9360.
30. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 707–717.
31. Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J et al. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis 2015; 6: e2020.
32. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun 2014; 5: 5671.
33. Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y et al. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene 2014; 33: 1325–1335.
34. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19: 439–448.
35. Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res 2013; 11: 759–767.
36. Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J et al. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood 2014; 123: 1516–1524.
37. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349–4354.
38. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013; 31: 3219–3225.
39. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188–194.
40. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533–5540.
41. Quesne JL, Jones J, Warren J, Dawson SJ, Ali HR, Bardwell H et al. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol 2012; 227: 306–314.
42. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847–865.
43. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1–9.
44. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593–601.
45. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327–1334.
46. Greene SB, Herschkowitz JI, Rosen JM. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol 2010; 7: 300–304.
47. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195–2200.
48. Chao CH, Chang CC, Wu MJ, Ko HW, Wang D, Hung MC et al. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 2014; 124: 3093–3106.
49. Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012; 181: 2188–2201.
50. Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R et al. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol 2014; 87: 579–597.
51. Zarogoulidis P, Petanidis S, Kioseoglou E, Domvri K, Anestakis D, Zarogoulidis K. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal 2015; 27: 1576–1588.
52. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011; 286: 16606–16614.
53. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298–307.
54. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439–442.
55. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13: 871–882.
56. Taraboletti G, Rusnati M, Ragona L, Colombo G. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010; 1: 662–673.
57. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2011; 30: 1205–1212.
58. Gan Y, Wientjes MG, Au JL. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006; 23: 1324–1331.
59. Zhou B, Ma R, Si W, Li S, Xu Y, Tu X et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett 2013; 333: 159–169.
60. Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y, Li PY et al. MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget 2015; 6: 29527–29542.
61. Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q et al. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol 2015; 33: 169.e1–169.e11.